Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Clinical trial NCT04808999 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04808999
- Sponsor
- Diwakar Davar
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-11
- Primary completion
- 2024-04-12
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.